Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

32 results about "Bexarotene" patented technology

Bexarotene is used to treat skin problems from a certain type of cancer (cutaneous T-cell lymphoma-CTCL).

Method for detecting impurity in bexarotene softgel by high performance liquid chromatography

The invention provides a method for detecting impurity in bexarotene softgel by high performance liquid chromatography. In the high performance liquid chromatography, mobile phases A and B are included; the mobile phase A includes acetonitrile and a 0.01M ammoniom acetate buffer in the proportion of 70 to 30; the mobile phase B includes acetonitrile and a 0.01M ammoniom acetate buffer in the proportion of 80 to 20; and the pH value of the ammoniom acetate buffer is 3.0. Via the detection method, the impurity in the bexarotene softgel can be detected simply and rapidly, different peaks can be separated effectively, and the detection method is also simple in operation and shorter in analysis time.
Owner:HUMANWELL PURACAP PHARM WUHAN CO LTD

Application of bexarotene or/and pharmaceutically acceptable salt thereof in preparation of anti-pulmonary arterial hypertension drugs

The invention relates to an application of bexarotene (4-[1-(5, 6, 7, 8-tetrahydro-3, 5, 5, 8, 8-pentamethyl-2-naphthyl) vinyl] benzoic acid) or/and a pharmaceutically acceptable salt thereof in preparation of anti-pulmonary arterial hypertension drugs. The chemical structural formula of bexarotene is shown as a formula I in the specification. According to the application, rat pulmonary artery smooth muscle cells are adopted for investigating the smooth muscle cell proliferation and migration inhibiting effect of bexarotene, and the result shows that bexarotene can obviously inhibit PASMCs proliferation and migration. The monocrotaline-induced rat pulmonary arterial hypertension model is adopted to investigate the anti-pulmonary arterial hypertension vascular remodeling of the bexarotene,and the result shows that the oral administration of the bexarotene can significantly inhibit the increase of the pulmonary arterial pressure and the right ventricular systolic pressure of rats, significantly reduce the NT-proBNP level in the rat plasma, can obviously inhibit thickening of pulmonary artery intima media and reduce the narrow level of pulmonary arteriole lumens, and a safe, effective and economical solution is provided for prevention and treatment of pulmonary arterial hypertension and pulmonary vascular remodeling.
Owner:上海宛文创业孵化器管理合伙企业(有限合伙)

Compositions and Methods for Preventing Joint Destruction in Osteoarthritis

InactiveUS20130035357A1Lower Level RequirementsInhibiting degradation of collagenBiocideAntipyreticJoint destructionBexarotene
The present invention is methods for inhibiting collagen destruction in joints of osteoarthritis patients. The methods are based on use of rexinoid compounds, in particular bexarotene, and their activity to inhibit synthesis of matrix metalloproteinases (MMPs) in affected tissue.
Owner:TRUSTEES OF DARTMOUTH COLLEGE THE

Preparation method of key intermediate of bexarotene

The invention relates to a preparation method of a key intermediate 4-[(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthalene)methoxyl]methyl benzoate (5) of new anti-cancer medicine bexarotene. The method comprises the steps that an intermediate 1,1,4,4,6-pentamethyl-1,2,3,4-tetrahydronaphthalene (4) and commercially available chemical materials of mono-methyl terephthlate, chlorinating agents of thionyl chloride or oxalyl chloride or the like and solvents of aluminum chloride, dichloromethane and the like are directly subjected to a one-step reaction, and the intermediate (5) is obtained. Please see the formula in the description. According to the preparation method of the key intermediate 4-[(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthalene)methoxyl]methyl benzoate (5) of the new anti-cancer medicine bexarotene, the reaction step is simplified, the raw materials are easy to obtain, the reaction condition is mild, the reaction yield is up to 95% (The literature method yield is 70%.), the product purity is larger than or equal to 98%, the step of preparing methoxycarbonyl benzoyl chloride through virulent phosphorus pentachloride in a literature method is omitted, a virulent and explosive chemical reagent nitromethane used for a stable reactant is removed, the production cost is reduced, the production process is simplified, and the preparation method is very suitable for industrialized mass production.
Owner:TIANJIN INSTITUTE OF PHARMA RESEARCH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products